Metiapine: A Double‐Blind Comparison with Chlorpromazine in Acute Schizophrenic Patients

RICHARD M. STEINBOOK, BURTON J. GOLDSTEIN, BENJAMIN BRAUZER, ALAN F. JACOBSON, SUSAN S. MORENO

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Sixty newly admitted acute schizophrenic patients were randomly assigned to a double blind trial of metiapine with a maximum dose of 450 mg per day vs a maximum daily dose of 900 mg chlorpromazine per day. At the conclusion of the study, 21 patients in each group showed marked to moderate improvement. There were significantly more marked improvers in the metiapine group than in the chlorpromazine group on the Physician's Posttreatment Global Impression. Evaluation by analysis of covariance of the Brief Psychiatric Rating Scale showed a significant difference between treatment groups favoring chlorpromazine on the item of blunted affect. The spectrum of side effects was similar in the two groups, except for six patients treated with metiapine who displayed tachycardia on the EKG. This pulse elevation was reflected in the group data and is probably dose related. In conclusion, both drugs appeared to be equally efficacious in the treatment of newly admitted acute schizophrenic patients.

Original languageEnglish (US)
Pages (from-to)700-704
Number of pages5
JournalThe Journal of Clinical Pharmacology
Volume15
Issue number10
DOIs
StatePublished - Oct 1975

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Metiapine: A Double‐Blind Comparison with Chlorpromazine in Acute Schizophrenic Patients'. Together they form a unique fingerprint.

Cite this